Inventor Search

=> d ibib abs hitstr l9 1-1

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:553417 HCAPLUS
DOCUMENT NUMBER: 133:144922
TITLE: Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4
INVENTOR(S): **Raza, Ali; Pears, John Stuart; Hutchinson, Howard Gerard; Schneck, Dennis; Baba, Takahiko; Touchi, Akira;** Yamaguchi, Yoshitaka
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Shionogi and Co. Ltd.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045817	A1	20000810	WO 2000-GB278	20000201
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2358632	AA	20000810	CA 2000-2358632	20000201
BR 2000007999	A	20011106	BR 2000-7999	20000201
EP 1185274	A1	20020313	EP 2000-901264	20000201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200100406	A	20021015	EE 2001-406	20000201
JP 2002536331	T2	20021029	JP 2000-596937	20000201
NO 2001003811	A	20011002	NO 2001-3811	20010803

PRIORITY APPLN. INFO.:
GB 1999-2593 A 19990206
GB 1999-21063 A 19990908
GB 1999-21064 A 19990908
WO 2000-GB278 W 20000201

AB The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid, or a pharmaceutically acceptable salt thereof, (the Agent) and a drug which is either an inducer, inhibitor, or substrate of cytochrome P 450, in particular cytochrome P 450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidemia in mammals, and medicaments contg. such a combination for use in such treatments.

IT **9035-51-2**, Cytochrome P450, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(3A4, inhibitor or inducer or substrate; dihydroxyheptenoate deriv.

therapeutic combination)
RN 9035-51-2 HCAPLUS
CN Cytochrome P 450 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **50-02-2**, Dexamethasone **50-06-6**, Phenobarbital, biological studies **50-18-0**, Cyclophosphamide **50-49-7**, Imipramine **52-53-9**, Verapamil **56-54-2**, Quinidine **57-41-0**, Phenytoin **57-63-6**, Ethinylestradiol **57-68-1**, Sulfadimidine **57-96-5**, Sulfinpyrazone **58-55-9**, biological studies **59-67-6**, Niacin, biological studies **71-63-6**, Digitoxin **74-79-3D**, L-Arginine, hydroxy derivs., biological studies **80-08-0**, Dapsone **81-81-2**, Warfarin **103-90-2**, Acetaminophen **114-07-8**, Erythromycin **137-58-6**, Lidocaine **156-08-1**, Benzphetamine **298-46-4**, Carbamazepine **302-79-4**, Retinoic acid **309-00-2**, Aldrin **439-14-5**, Diazepam **480-41-1**, Naringenin **637-07-0**, Clofibrate **1951-25-3**, Amiodarone **2751-09-9**, Troleandomycin **3778-73-2**, Ifosphamide **13292-46-1**, Rifampin **13311-84-7**, Flutamide **21829-25-4**, Nifedipine **22916-47-8**, Miconazole **23593-75-1**, Clotrimazole **25812-30-0**, Gemfibrozil **28911-01-5**, Triazolam **29767-20-2**, Teniposide **33419-42-0**, Etoposide **41859-67-0**, Bezafibrate **42399-41-7**, Diltiazem **49562-28-9**, Fenofibrate **51333-22-3**, Budesonide **53123-88-9**, Rapamycin **59467-70-8**, Midazolam **60282-87-3**, Gestodene **65277-42-1**, Ketoconazole **68291-97-4**, Zonisamide **68844-77-9**, Astemizole **71195-58-9**, Alfentanil **73590-58-6**, Omeprazole **75330-75-5**, Lovastatin **79217-60-0**, Cyclosporin **79794-75-5**, Loratidine **84625-61-6**, Itraconazole **89778-26-7**, Toremifene **103577-45-3**, Lansoprazole **104987-11-3**, Tacrolimus **114798-26-4**, Losartan **123482-22-4**, Zatosetron **147098-20-2** **287714-41-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dihydroxyheptenoate deriv. therapeutic combination)
RN 50-02-2 HCAPLUS
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50-06-6 HCAPLUS
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 50-18-0 HCAPLUS
CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9CI) (CA INDEX NAME)



RN 50-49-7 HCAPLUS
CN 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 52-53-9 HCAPLUS
CN Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 56-54-2 HCAPLUS
CN Cinchonan-9-ol, 6'-methoxy-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 57-41-0 HCAPLUS
CN 2,4-Imidazolidinedione, 5,5-diphenyl- (9CI) (CA INDEX NAME)



RN 57-63-6 HCAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-68-1 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-(4,6-dimethyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 57-96-5 HCAPLUS
CN 3,5-Pyrazolidinedione, 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]- (6CI,

7CI, 8CI, 9CI) (CA INDEX NAME)



RN 58-55-9 HCAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 59-67-6 HCAPLUS
CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)



RN 71-63-6 HCAPLUS
CN Card-20(22)-enolide, 3-[(O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy]-14-hydroxy-, (3.beta.,5.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 74-79-3 HCAPLUS
CN L-Arginine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 80-08-0 HCAPLUS
CN Benzenamine, 4,4'-sulfonylbis- (9CI) (CA INDEX NAME)



RN 81-81-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)- (9CI) (CA INDEX NAME)



RN 103-90-2 HCAPLUS
CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 114-07-8 HCAPLUS
CN Erythromycin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 137-58-6 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 156-08-1 HCAPLUS
CN Benzeneethanamine, N,.alpha.-dimethyl-N-(phenylmethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 298-46-4 HCAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 302-79-4 HCAPLUS
CN Retinoic acid (6CI, 9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 309-00-2 HCAPLUS
CN 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1R,4S,4aS,5S,8R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439-14-5 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 480-41-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 637-07-0 HCAPLUS
CN Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 1951-25-3 HCAPLUS
CN Methanone, (2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]- (9CI) (CA INDEX NAME)



RN 2751-09-9 HCAPLUS
CN Oleandomycin, triacetate (ester) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3778-73-2 HCAPLUS
CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide (9CI) (CA INDEX NAME)



RN 13292-46-1 HCAPLUS
CN Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 13311-84-7 HCAPLUS
CN Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 21829-25-4 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester (9CI) (CA INDEX NAME)



RN 22916-47-8 HCAPLUS
CN 1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 23593-75-1 HCAPLUS
CN 1H-Imidazole, 1-[(2-chlorophenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)



RN 25812-30-0 HCAPLUS
CN Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 28911-01-5 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 29767-20-2 HCAPLUS
CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-.beta.-D-glucopyranosyl]oxy]-, (5R,5aR,8aR,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 33419-42-0 HCAPLUS
CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 41859-67-0 HCAPLUS
CN Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 42399-41-7 HCAPLUS
CN 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 51333-22-3 HCAPLUS
CN Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53123-88-9 HCAPLUS
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

RN 59467-70-8 HCAPLUS
CN 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 60282-87-3 HCAPLUS
CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 65277-42-1 HCAPLUS
CN Piperazine, 1-acetyl-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 68291-97-4 HCAPLUS
CN 1,2-Benzisoxazole-3-methanesulfonamide (9CI) (CA INDEX NAME)



RN 68844-77-9 HCAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 71195-58-9 HCAPLUS
CN Propanamide, N-[1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4-piperidinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 73590-58-6 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 75330-75-5 HCAPLUS
CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 79217-60-0 HCAPLUS
CN Cyclosporin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 79794-75-5 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 84625-61-6 HCAPLUS
CN 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 89778-26-7 HCAPLUS
CN Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 103577-45-3 HCAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 104987-11-3 HCAPLUS
CN 15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 114798-26-4 HCAPLUS
CN 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 123482-22-4 HCAPLUS
CN 7-Benzofurancarboxamide, 5-chloro-2,3-dihydro-2,2-dimethyl-N-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 147098-20-2 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



●1/2 Ca

Requested

RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **9028-35-7**, HMG-CoA reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; dihydroxyheptenoate deriv. therapeutic combination)
RN 9028-35-7 HCAPLUS
CN Reductase, hydroxymethylglutaryl coenzyme A (reduced nicotinamide adenine dinucleotide phosphate) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d que stat l13
L10             1 SEA FILE=REGISTRY ABB=ON  287714-41-4/RN
L11             1 SEA FILE=REGISTRY ABB=ON  FENOFIBRATE/CN
L12            17 SEA FILE=HCAPLUS ABB=ON  L10 AND (L11 OR ?FENOFIBRATE?)
L13            15 SEA FILE=HCAPLUS ABB=ON  L12 AND (?THERAP? OR ?PHARM?)

=> d ibib abs hitstr l13 1-15

L13  ANSWER 1 OF 15  HCAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2003:633275  HCAPLUS
TITLE:                    Novel anticholesterol compositions and method for
                          using same
INVENTOR(S):              Dudley, Robert; Liao, Shutsung; Song, Ching
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S.
                          Ser. No. 137,695.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   8
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.   DATE
     ----------------  ----  --------      ---------------   --------
     US 2003153541      A1   20030814      US 2002-174934    20020619
     WO 9922728         A1   19990514      WO 1998-US23041   19981030
          W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6576660         B1   20030610      US 2000-530443    20000428
     US 2002107233      A1   20020808      US 2002-72128     20020208
     US 2002193357      A1   20021219      US 2002-137695    20020502
PRIORITY APPLN. INFO.:                  US 1997-63770P    P  19971031
                                        WO 1998-US23041   W  19981030
                                        US 1999-131728P   P  19990430
                                        US 2000-530443    A2 20000428
                                        US 2000-560236    A2 20000428
                                        US 2001-267493P   P  20010208
                                        US 2001-288643P   P  20010503
                                        US 2001-348020P   P  20011108
                                        US 2002-72128     A2 20020208
                                        US 2002-137695    A2 20020502
```

AB Disclosed are compns., methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concn., for example, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia, cholesterol gallstones, lipid storage diseases, obesity, and diabetes. The compns., methods, combinations, and kits of the present invention are **pharmaceutical** compns. comprising at least two of an LXR receptor modulator, a **therapeutically** effective amt. of a catechin, and/or a **therapeutically** effective amt. of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, a fibric acid deriv., niacin, a bile-acid sequestrant, an absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone compd., and an unsatd. omega-3

fatty acid.
IT INDEXING IN PROGRESS
IT **49562-28-9, Fenofibrate 287714-41-4,** Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticholesterol compns. contg. LXR modulators and lipid regulating agents)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:320036 HCAPLUS
DOCUMENT NUMBER: 138:338498
TITLE: Preparation of human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
INVENTOR(S): Natarajan, Sesha I.; Bastos, Margarita M.; Bernatowicz, Michael S.; Mapelli, Claudio; Lee, Ving; Ewing, William R.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033671	A2	20030424	WO 2002-US33386	20021018

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-342015P P 20011018
OTHER SOURCE(S): MARPAT 138:338498

AB The invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics A-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Y-Z-B [Xaa1-Xaa9 are naturally or non-naturally occurring amino acid residues; Y and Z are amino acid residues which may be substituted; A and B are optionally present; A is H, an amino acid or peptide contg. .apprx. 1-15 amino acid residues, an R group [H, (cyclo)alkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, (hetero)aryl, arylalkyl, aryloxyalkyl, heteroarylalkyl, or heteroaryloxyalkyl], an RCO (amide) group, a carbamate group, a urea, a sulfonamido, or an aminosulfonyl group; B is OH, alkoxy, etc., an amino or amino acid residue, or a peptide contg. from 1-15 amino acid residues, terminating at the C-terminus as a carboxamide, ester, carboxyl, or an amino alc.] that mimic the biol. activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders assocd. with GLP activity. These chem.-modified peptides stimulate insulin secretion in type II diabetics and produce other beneficial insulinotropic responses, while exhibiting increased stability to proteolytic cleavage making them ideal **therapeutic** candidates for oral or parenteral administration. A method of prepg. the polypeptides comprises replacing the message sequence of the polypeptide with a variant message sequence capable of inducing receptor mediated signal transduction. An example is claimed peptide H-AEGTFTSD-Bip(2-Et)-Bip(2-Me)-NH2 (Bip = biphenylalanine residue).

IT **49562-28-9, Fenofibrate 287714-41-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of human glucagon-like-peptide-1 mimics for use in treatment of diabetes and related conditions)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:261607 HCAPLUS
DOCUMENT NUMBER: 138:265599
TITLE: Screening and selection methods for statin drug combinations
INVENTOR(S): Prueksaritanont, Thomayant
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026573	A2	20030403	WO 2002-US30004	20020920

W: CA, JP, US
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR

PRIORITY APPLN. INFO.: US 2001-324485P P 20010924
US 2002-378612P P 20020507

AB A method for screening statins in their open acid form to det. the susceptibility of each tested statin to metabolic glucuronidation is provided. Also provided is a method for detg. if a non-statin **pharmaceutical** drug co-administered with a statin that is susceptible to metabolic glucuronidation in its open acid form, will inhibit the glucuronidation of the statin and thereby increase the risk of an adverse drug interaction.

IT **49562-28-9, Fenofibrate 287714-41-4,** Rosuvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(screening and selection methods for statin drug combinations)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:202655 HCAPLUS
DOCUMENT NUMBER: 138:221784
TITLE: Preparation of O-pyrazole glucoside SGLT2 inhibitors as antidiabetic agents
INVENTOR(S): Washburn, William N.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020737	A1	20030313	WO 2002-US28480	20020905

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003087843 A1 20030508 US 2002-235336 20020905

PRIORITY APPLN. INFO.: US 2001-317280P P 20010905

OTHER SOURCE(S): MARPAT 138:221784

GI



I

AB O-pyrazole glucosides I, wherein A is CH2 or (CH2)2; R1 is hydrogen, arylalkyl, alkenyl, or alkyl; R2 is alkyl or perfluoroalkyl; and R3 and R4 are independently hydrogen, OH, alkoxy, O-aryl, OCH2-aryl, alkyl, cycloalkyl, CF3, -OCHF2, -3,4-(OCH2O), -OCF3, halogen, -CN, carboxylate, -CO2H, acyl, amide, sulfonamide, Aryl, sulfide, sulfoxide; R3 and R4 together with the carbons to which they are attached form an annulated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, SO2. Further provided are methods of using such compds. for the treatment of diabetes and related diseases, and to **pharmaceutical** compns. contg. such compds. Thus I (A = CH2; R1 = R3 = R4 = H; R2 = Me) was prepd. as antidiabetic, anti-obesity, anti-hypertensive, anti-atherosclerotic, and lipid-lowering agent.

IT **49562-28-9, Fenofibrate 287714-41-4,** Visastatin
RL: BSU (Biological study, unclassified); BIOL (Biological study) (prepn. of O-pyrazole glucoside SGLT2 inhibitors as antidiabetic agents)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:154239 HCAPLUS
DOCUMENT NUMBER: 138:180718
TITLE: Combination of a soluble guanylate cyclase stimulant and hypolipemic agent for the treatment of coronary heart disease and other diseases
INVENTOR(S): Bischoff, Hilmar; Stasch, Johannes-Peter
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015770	A1	20030227	WO 2002-EP8701	20020805

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10140421 A1 20030306 DE 2001-10140421 20010817
PRIORITY APPLN. INFO.: DE 2001-10140421 A 20010817.
OTHER SOURCE(S): MARPAT 138:180718

AB The invention relates to a combination prepn. that, as **pharmaceutically** active constituents, contains at least one active ingredient constituent A and at least one active ingredient constituent B, whereby active ingredient constituent A is a direct stimulator of the sol. guanylate cyclase, and active ingredient constituent B is a lipid reducer. Both active ingredient constituents A and B can be used either simultaneously or in a temporally graduated manner, i.e. exist as a functional unit or sep. from one another.

IT **49562-28-9, Fenofibrate 287714-41-4,** Rosuvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of a sol. guanylate cyclase stimulant and hypolipemic agent for treatment of coronary heart disease and other diseases)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:109641 HCAPLUS
DOCUMENT NUMBER: 138:362008
TITLE: Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor
AUTHOR(S): Olsson, Anders G.; McTaggart, Fergus; Raza, Ali
CORPORATE SOURCE: University Hospital, Linkoping, Swed.
SOURCE: Cardiovascular Drug Reviews (2002), 20(4), 303-328
CODEN: CDREEA; ISSN: 0897-5957
PUBLISHER: Neva Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Rosuvastatin, a new statin, has been shown to possess a no. of advantageous **pharmacol.** properties, including enhanced HMG-CoA reductase binding characteristics, relative hydrophilicity, and selective uptake into/activity in hepatic cells. Cytochrome P 450 (CYP) metab. of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clin. significant **pharmacokinetic** drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes. Dose-ranging studies in hypercholesterolemic patients demonstrated dose-dependent effects in reducing low-d. lipoprotein cholesterol (LDL-C) (up to 63%), total cholesterol, and apolipoprotein (apo) B across a 1- to 40-mg dose range and a significant 8.4% addnl. redn. in LDL-C, compared with atorvastatin, across the dose ranges of the two agents. Rosuvastatin has also been shown to be highly effective in reducing LDL-C, increasing high-d. lipoprotein cholesterol (HDL-C), and producing favorable modifications of other elements of the atherogenic lipid profile in a wide range of dyslipidemic patients. In patients with mild to moderate hypercholesterolemia, rosuvastatin has been shown to produce large decreases in LDL-C at starting doses, thus reducing the need for subsequent dose titrn., and to allow greater percentages of patients to attain lipid goals, compared with available statins. The substantial LDL-C redns. and improvements in other lipid measures with rosuvastatin treatment should facilitate achievement of lipid goals and reduce the requirement for combination **therapy** in patients with severe hypercholesterolemia. In addn., rosuvastatin's effects in reducing triglycerides, triglyceride-contg. lipoproteins, non-HDL-C, and LDL-C and

increasing HDL-C in patients with mixed dyslipidemia or elevated triglycerides should be of considerable value in enabling achievement of LDL-C. And non-HDL-C goals in the numerous patients with combined dyslipidemias or metabolic syndrome who require lipid-lowering **therapy**. Rosuvastatin is well tolerated alone, and in combination with **fenofibrate**, extended-release niacin, and cholestyramine, and has a safety profile similar to that of currently marketed statins. A large, long-term clin. trials program is under way to investigate the effects of rosuvastatin on atherosclerosis and cardiovascular morbidity and mortality.

IT **287714-41-4**, Rosuvastatin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitor rosuvastatin for treatment of dyslipidemias)

RN 287714-41-4 HCAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:818798 HCAPLUS
DOCUMENT NUMBER: 138:395431
TITLE: Effects of fibrates on metabolism of statins in human hepatocytes
AUTHOR(S): Prueksaritanont, Thomayant; Tang, Cuyue; Qiu, Yue; Mu, Lillian; Subramanian, Raju; Lin, Jiunn H.
CORPORATE SOURCE: Department of Drug Metabolism, Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: Drug Metabolism and Disposition (2002), 30(11), 1280-1287
CODEN: DMDSAI; ISSN: 0090-9556
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal

LANGUAGE: English

AB This study investigated the metabolic interaction between fibrates and statin hydroxy acids in human hepatocytes. Gemfibrozil (GFZ) modestly affected the formation of .beta.-oxidative products and CYP3A4-mediated oxidative metabolites of simvastatin hydroxy acid (SVA) but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of a .beta.-oxidn. product (IC50 .apprx.50 and 15 .mu.M, resp.). In contrast, **fenofibrate** had a minimal effect on all the metabolic pathways of SVA. GFZ also significantly inhibited (IC50 .apprx.50-60 .mu.M) the oxidn. of cerivastatin (CVA) and rosuvastatin (RVA), but not of atorvastatin (AVA), while effectively decreasing (IC50 .apprx.30 to 60 .mu.M) the lactonization of all three statins. As was obsd. previously with other statin hydroxy acids, RVA underwent significant glucuronidation to form an acyl glucuronide conjugate and lactonization to form RVA lactone in human liver microsomes and by UGT 1A1 and 1A3. While GFZ is not an inhibitor of CYP3A4, it is a competitive inhibitor (K1 = 87 .mu.M) of CYP2C8, a major catalyzing enzyme for CVA oxidn. These results suggest that (1) the **pharmacokinetic** interaction obsd. between GFZ and statins was not likely mediated by the inhibitory effect of GFZ on the .beta.-oxidn., but rather by its effect primarily on the glucuronidation and non-CYP3A-mediated oxidn. of statin hydroxy acids, and (2) there is a p.d. between fibrates in their ability to affect the **pharmacokinetics** of statins, and among statins in their susceptibility to metabolic interactions with GFZ in humans.

IT **49562-28-9, Fenofibrate**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(effects of fibrates on metab. of statins in human hepatocytes)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



IT **287714-41-4,** Rosuvastatin
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(effects of fibrates on metab. of statins in human hepatocytes)

RN 287714-41-4 HCAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:813924 HCAPLUS
DOCUMENT NUMBER: 137:311200
TITLE: Preparation of 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV
INVENTOR(S): Sulsky, Richard B.; Robl, Jeffrey A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083128	A1	20021024	WO 2002-US10936	20020405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002183367	A1	20021205	US 2002-107279	20020326
US 6573287	B2	20030603		

PRIORITY APPLN. INFO.: US 2001-283438P P 20010412
OTHER SOURCE(S): MARPAT 137:311200
GI



I



II

AB The invention describes dipeptidyl peptidase IV (DP 4) inhibiting compds. I [n is 0 or 1; X is H or CN; Y is N, NH or O; Z is CH2 when Y is O or NH, with Y-Z forming a single bond, and Z is CH when Y is N, with Y-Z forming a double bond; R1-R4 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, bicycloalkylalkyl, alkylthioalkyl, arylalkylthioalkyl, cycloalkenyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl or cycloheteroalkylalkyl, which may be substituted; R1 may combine with R3 or R4 to form a ring (CR5R6)2-6 or (CR7R8)3-6, resp., where R5-R8 = H, OH, alkoxy, alkyl, aryl, etc.] and their **pharmaceutically**-acceptable salts or prodrug esters. A method is also provided for treating diabetes and related diseases, employing a DP 4 inhibitor I, optionally in combination with other **therapeutic** agents, including an antidiabetic, hypolipidemic, or anti-obesity agent. Thus, coupling of sultam-protected 1,2-pyrazoline-3-carboxamide with (S)-N-(tert-butoxycarbonyl)cyclohexylglycine (HOAt, Et3N, and EDAC in CH2Cl2), followed by sultam cleavage with methanolic ammonia, amide conversion to nitrile using imidazole, and deprotection, afforded II.TFA.

IT **49562-28-9, Fenofibrate 287714-41-4,** Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid modulating agent; prepn. of oxazoline and pyrazoline-based inhibitors of dipeptidyl peptidase IV)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:813874 HCAPLUS
DOCUMENT NUMBER: 137:311199
TITLE: Amino acid complexes of C-aryl glucosides for treatment of diabetes
INVENTOR(S): Gougoutas, Jack Z.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083066	A2	20021024	WO 2002-US11066	20020408
WO 2002083066	A3	20030306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003064935	A1	20030403	US 2002-117914	20020408

PRIORITY APPLN. INFO.: US 2001-283097P P 20010411
OTHER SOURCE(S): MARPAT 137:311199
GI



I

AB Cryst. complexes are obtained from 1:1 or 2:1 mixts. of either the (D) or (L) enantiomer of natural amino acids and compds. of formula I [R1, R2, R2a = H, OH, OR5, alkyl, OCHF2, OCF3, SR5a, halogen; R3, R4 = H, OH, OR5b, alkyl, cycloalkyl, CF3, OCHF2, OCF3, halogen, CONR6R6a, CO2R5c, CO2H, COR6b, CH(OH)R6c, CH(OR5d)R6d, CN, NHCOR5e, NHSO2R5f, NHSO2-aryl, SR5g, SOR5h, SO2R5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms (N, O, S, SO, and/or SO2), or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring; R5, R5a-R5i are independently alkyl; R6, R6a-R6d are independently H, alkyl, aryl, alkylaryl or cycloalkyl, or NR6R6a form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring]. A method is also provided for treating diabetes and related diseases employing an SGLT2 (sodium dependent glucose transporters found in the intestine and kidney) inhibiting amt. of the above complex alone or in combination with another antidiabetic agent or other **therapeutic** agent. Thus, I (R1 = 4-Me, R4 = 4-OCHF2, R2, R2a, R3 = H) was prepd. by a multistep procedure starting from o-toluic acid, anisole, 2,3,4,6-tetra-O-benzyl-.beta.-D-glucolactone, and CHF2Cl and treated with L-phenylalanine to form the cryst. 1:1 complex.

IT **49562-28-9, Fenofibrate 287714-41-4,** Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of amino acid/C-aryl glucoside complexes for treatment of diabetes and related diseases)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:736927 HCAPLUS
DOCUMENT NUMBER: 137:247879
TITLE: Preparation of antidiabetic agents C-aryl glucoside as human SGLT2 inhibitors
INVENTOR(S): Ellsworth, Bruce; Washburn, William N.; Sher, Philip M.; Wu, Gang; Meng, Wei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,414,126.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002137903	A1	20020926	US 2002-151436	20020520
US 6515117	B2	20030204		
US 6414126	B1	20020702	US 2000-679027	20001004

PRIORITY APPLN. INFO.: US 1999-158773P P 19991012
US 2000-194615P P 20000405
US 2000-679027 A2 20001004

GI



I

AB An SGLT2 inhibiting compd. is provided having the formula I method is also provided for treating diabetes and related diseases employing an SGLT2

inhibiting amt. of the above compd. alone or in combination with another antidiabetic agent or other **therapeutic** agent (no data). 1A **pharmaceutical** combination comprising an SGLT2 inhibitor compd. and an antidiabetic agent other than an SGLT2 inhibitor, for treating the complications of diabetes, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an antiatherosclerotic agent, and/or a lipid-lowering agent (no data). A method for treating or delaying the progression or onset of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis or hypertension, or for increasing high d. lipoprotein levels, which comprises administering to a mammalian species in need of treatment a **therapeutically** effective amt. of a compd (no data).

IT **49562-28-9, Fenofibrate 287714-41-4,** Rosuvastatin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of antidiabetic agents C-aryl glucosides as human SGLT2 inhibitors)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:574956 HCAPLUS
DOCUMENT NUMBER: 137:129904
TITLE: Combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases
INVENTOR(S): Kosoglou, Teddy; Davis, Harry R.; Picard, Gilles Jean Bernard
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058732	A2	20020801	WO 2002-US2009	20020125
WO 2002058732	A3	20030703		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002151536	A1	20021017	US 2002-57323	20020125
US 2002192203	A1	20021219	US 2002-136968	20020501

PRIORITY APPLN. INFO.: US 2001-264396P P 20010126
US 2001-323839P P 20010921
US 2002-57323 A3 20020125

OTHER SOURCE(S): MARPAT 137:129904

AB The present invention provides compns., **therapeutic** combinations and methods including: (a) at least one peroxisome proliferator-activated receptor (PPAR) activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. A tablet contained azetidinone 10, lactose monohydrate 55, microcryst. cellulose 20, povidone 4, croscarmellose sodium 8, sodium lauryl sulfate 2, and magnesium stearate 1 mg. The tablet can be coadministered with a tablets contg. a PPAR activator such as ezetimibe. Synthetic prepn. of ezetimibe from fluorophenylazetidinone derivs. is described. The coadministration of 10 mg of ezetimibe with 200 mg of **fenofibrate** was well tolerated and caused a significant redn. in LDL-C as compared to either drug alone or placebo.

IT **49562-28-9, Fenofibrate 287714-41-4,** Rosuvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:540258 HCAPLUS
DOCUMENT NUMBER: 137:109267
TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002094977	A1	20020718	US 2001-7407	20011204
US 2002013334	A1	20020131	US 2001-875155	20010606

PRIORITY APPLN. INFO.: US 2000-211595P P 20000615
US 2001-875155 A2 20010606
OTHER SOURCE(S): MARPAT 137:109267
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO2, NR7; Z = HOCHCH2CH(OH)CH2CO2R3, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H, alkyl, metal ion; R4 = H, halo, CF3, etc.; R7 = H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepd. as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

IT **49562-28-9, Fenofibrate 287714-41-4,** Rosuvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministered agents; prepn. of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:392237 HCAPLUS
DOCUMENT NUMBER: 136:401651
TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002061901	A1	20020523	US 2001-8154		20011204
US 2002028826	A1	20020307	US 2001-875218		20010606
PRIORITY APPLN. INFO.:			US 2000-211594P	P	20000615
			US 2001-875218	A2	20010606

OTHER SOURCE(S): MARPAT 136:401651
GI



I



II

AB The title compds. I and their **pharmaceutically** acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH2CR7(OH)CH2CO2R3 or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH2)x and/or (CH2)y together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H or lower alkyl; R4 = H, halo, CF3, OH, alkyl, alkoxy, CO2H, (un)substituted NH2, cyano, (un)substituted CONH2, etc.; R7 = H, alkyl]. The compds. are HMG-CoA reductase inhibitors, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement **therapy**, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Prepns. of several compds. are described. For instance, a multistep synthesis of fused pyridine deriv. II is reported. Compds. I may be used in a manner similar to atorvastatin, pravastatin, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain **pharmacol.** classes, as inhibitors of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.

IT **49562-28-9, Fenofibrate 287714-41-4,** Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**therapeutic** compns. also contg.; prepn. of fused pyridine derivs. as HMG-CoA reductase inhibitors)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:240538 HCAPLUS
DOCUMENT NUMBER: 136:268166
TITLE: Spray drying process for preparation of **fenofibrate** compositions
INVENTOR(S): Pace, Gary; Mishra, Awadhesh K.; Snow, Robert A.; Parikh, Indu; Guivarc'h, Pol-Henri
PATENT ASSIGNEE(S): RTP Pharma Inc., USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024169	A1	20020328	WO 2001-US12746	20010420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001062945	A5	20020402	AU 2001-62945	20010420
US 2002056206	A1	20020516	US 2001-838593	20010420
WO 2002067901	A1	20020906	WO 2001-US12747	20010420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002161032	A1	20021031	US 2001-838583 20010420
US 6534088	B2	20030318	
EP 1322289	A1	20030702	EP 2001-937182 20010420

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:
US 2000-234186P P 20000920
US 2000-241761P P 20001020
US 2001-270157P P 20010222
WO 2001-US12746 W 20010420

AB The present invention relates to a novel spray drying process for the prepn. of **pharmaceutical** compns. contg. small particles of phospholipid-stabilized **fenofibrate**. This invention also relates to spray dried powd. compns. prepd. according to this process and to dosage forms of **fenofibrate** (capsules, tablets, powders, granules, and dispersions) prepd. from these powd. compns. The powd. compns. and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of **fenofibrate** active species among fed and fasted patients when administered orally. An admixt. of 3% Lipoid E80 as the surfactant and 10% **fenofibrate** is homogeneously dispersed in pH 8.0 10 mM aq. phosphate buffer by using a high-shear mixer for 30 min. Mannitol (10%) is then added and the admixt. is heated to 95.degree. during continuous high shear mixing. The heated suspension is then homogenized for 10 batch vol. cycles or passes by using a microfluidizer to form a heated homogenate contg. the drug. After 10 passes, the heated homogenate is then spray dried to produce a dried powder contg. Lipoid E80-stabilized microparticles of **fenofibrate** in mannitol.

IT **49562-28-9**, **Fenofibrate**
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spray drying for prepn. of **fenofibrate** compns.)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



IT **287714-41-4**, Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spray drying for prepn. of **fenofibrate** compns.)

RN 287714-41-4 HCAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:553417 HCAPLUS
DOCUMENT NUMBER: 133:144922
TITLE: Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4
INVENTOR(S): Raza, Ali; Pears, John Stuart; Hutchinson, Howard Gerard; Schneck, Dennis; Baba, Takahiko; Touchi, Akira; Yamaguchi, Yoshitaka
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Shionogi and Co. Ltd.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045817	A1	20000810	WO 2000-GB278	20000201
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2358632	AA	20000810	CA 2000-2358632	20000201
BR 2000007999	A	20011106	BR 2000-7999	20000201
EP 1185274	A1	20020313	EP 2000-901264	20000201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200100406	A	20021015	EE 2001-406	20000201

JP 2002536331	T2	20021029	JP 2000-596937	20000201
NO 2001003811	A	20011002	NO 2001-3811	20010803

PRIORITY APPLN. INFO.:

GB 1999-2593	A	19990206
GB 1999-21063	A	19990908
GB 1999-21064	A	19990908
WO 2000-GB278	W	20000201

AB The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid, or a **pharmaceutically** acceptable salt thereof, (the Agent) and a drug which is either an inducer, inhibitor, or substrate of cytochrome P 450, in particular cytochrome P 450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidemia in humans who are receiving immunosuppressive **chemotherapy**. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidemia in mammals, and medicaments contg. such a combination for use in such treatments.

IT **49562-28-9, Fenofibrate 287714-41-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dihydroxyheptenoate deriv. **therapeutic** combination)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 17:37:54 ON 27 AUG 2003)

     FILE 'HCAPLUS' ENTERED AT 17:39:55 ON 27 AUG 2003
                  E RAZA ALI/AU
L1              9 S E3-4
                  E PEARS JOHN S/AU
L2              8 S E2-4
                  E HUTCHINSON HOWARD G/AU
L3             13 S E3-4
                  E SCHNECK DENNIS/AU
L4             26 S E3-4
                  E BABA TAKAHIKO/AU
L5             22 S E3-4
                  E TOUCHI AKIRA/AU
L6             33 S E2-3
L7              1 S L1 AND L2 AND L3 AND L4 AND L5 AND L6
                  SELECT RN L7 1-1

     FILE 'REGISTRY' ENTERED AT 17:41:40 ON 27 AUG 2003
L8             63 S E1-63

     FILE 'HCAPLUS' ENTERED AT 17:41:53 ON 27 AUG 2003
L9              1 S L7 AND L8

     FILE 'REGISTRY' ENTERED AT 17:57:12 ON 27 AUG 2003
L10             1 S 287714-41-4/RN
                  E FENOFIBRATE/CN
L11             1 S E3

     FILE 'HCAPLUS' ENTERED AT 17:59:19 ON 27 AUG 2003
L12            17 S L10 AND (L11 OR ?FENOFIBRATE?)
L13            15 S L12 AND (?THERAP? OR ?PHARM?)

     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO' ENTERED AT
     18:00:48 ON 27 AUG 2003

     FILE 'HCAPLUS' ENTERED AT 18:01:44 ON 27 AUG 2003
```

```
=> d que stat l14
L10           1 SEA FILE=REGISTRY ABB=ON  287714-41-4/RN
L11           1 SEA FILE=REGISTRY ABB=ON  FENOFIBRATE/CN
L12          17 SEA FILE=HCAPLUS ABB=ON  L10 AND (L11 OR ?FENOFIBRATE?)
L13          15 SEA FILE=HCAPLUS ABB=ON  L12 AND (?THERAP? OR ?PHARM?)
L14           2 SEA L13


=> d ibib abs l14 1-2

L14  ANSWER 1 OF 2  BIOSIS  COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER:   2003:230319  BIOSIS
DOCUMENT NUMBER:    PREV200300230319
TITLE:              An open-label, randomized, three-way crossover trial of the
                    effects of coadministration of rosuvastatin and
                    fenofibrate on the pharmacokinetic
                    properties of rosuvastatin and fenofibric acid in healthy
                    male volunteers.
AUTHOR(S):          Martin, Paul D. (1); Dane, Aaron L.; Schneck, Dennis W.;
                    Warwick, Michael J.
CORPORATE SOURCE:   (1) AstraZeneca, Mereside, Alderley Park, Macclesfield,
                    Cheshire, SK10 4TG, UK: paul.martin@astrazeneca.com UK
SOURCE:             Clinical Therapeutics, (February 2003, 2003) Vol. 25, No.
                    2, pp. 459-471. print.
                    ISSN: 0149-2918.
DOCUMENT TYPE:      Article
LANGUAGE:           English
AB   Background: Rosuvastatin and fenofibrate are lipid-regulating
     agents with different modes of action. Patients with dyslipidemia who have
     not achieved treatment targets with monotherapy may benefit from
     the combination of these agents. Objective: The effect of coadministration
     of rosuvastatin and fenofibrate on the steady-state
     pharmacokinetics of rosuvastatin and fenofibric acid (the active
     metabolite of fenofibrate) was assessed in healthy volunteers.
     Methods: This was an open-label, randomized, 3-way crossover trial
     consisting of three 7-day treatment periods. Healthy male volunteers
     received one of the following treatment regimens in each period:
     rosuvastatin 10 mg orally once daily; fenofibrate 67 mg orally
     TID; and rosuvastatin+fenofibrate dosed as above. The
     steady-state pharmacokinetics of rosuvastatin and fenofibric
     acid, both as substrate and as interacting drug, were investigated on day
     7 of dosing. Treatment effects were assessed by construction of 90% CIs
     around the ratios of the geometric least-square means for rosuvastatin+
     fenofibrate/rosuvastatin and rosuvastatin+fenofibrate/
     fenofibrate for the area under the plasma concentration-time curve
     (AUC) and maximum plasma concentration (derived from analysis of variance
     of log-transformed parameters). Results: Fourteen healthy male volunteers
     participated in the study. When rosuvastatin was coadministered with
     fenofibrate, there were minor increases in the AUC from 0 to 24
     hours and maximum concentration (Cmax) of rosuvastatin: the respective
     geometric least-square means increased by 7% (90% CI, 1.00-1.15) and 21%
     (90% CI, 1.14-1.28). The pharmacokinetic parameters of
     fenofibric acid were similar when fenofibrate was dosed alone
     and with rosuvastatin: the geometric least-square means for fenofibric
     acid AUC from 0 to 8 hours and Cmax decreased by 4% (90% CI, 0.90-1.02)
     and 9% (90% CI, 0.84-1.00), respectively. The treatments were well
     tolerated alone and in combination. Conclusion: Coadministration of
     rosuvastatin and fenofibrate produced minimal changes in
```

rosuvastatin and fenofibric acid exposure.

L14 ANSWER 2 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2002:568661 BIOSIS
DOCUMENT NUMBER: PREV200200568661
TITLE: Rosuvastatin alone and in combination with **fenofibrate** in hyperlipidaemic patients with type 2 diabetes.
AUTHOR(S): Durrington, P. (1); Hamann, A.; Tuomilehto, J.; Smith, K.; Kallend, D.
CORPORATE SOURCE: (1) University of Manchester, Manchester UK
SOURCE: Diabetologia, (August, 2001) Vol. 44, No. Supplement 1, pp. A165. print.
Meeting Info.: 37th Annual Meeting of the European Association for the Study of Diabetes Glasgow, Scotland, UK September 09-13, 2001 European Association for the Study of Diabetes
. ISSN: 0012-186X.
DOCUMENT TYPE: Conference
LANGUAGE: English

```
=> d his ful

     FILE 'REGISTRY' ENTERED AT 17:57:12 ON 27 AUG 2003
L10           1 SEA ABB=ON  287714-41-4/RN
                E FENOFIBRATE/CN
L11           1 SEA ABB=ON  FENOFIBRATE/CN

     FILE 'HCAPLUS' ENTERED AT 17:59:19 ON 27 AUG 2003
L12          17 SEA ABB=ON  L10 AND (L11 OR ?FENOFIBRATE?)
                D AU 1-17
L13          15 SEA ABB=ON  L12 AND (?THERAP? OR ?PHARM?)

     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO' ENTERED AT
     18:02:36 ON 27 AUG 2003
L14           2 SEA ABB=ON  L13
L15           2 SEA ABB=ON  L12
L16           2 SEA ABB=ON  L14 OR L15
```

Requested compd – see attached display

15 cits from CA files

2 cits from other databases

Requested compd., located in "inventor search" and searched via Reg. No.


```
=> d l10
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y


L10  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   287714-41-4  REGISTRY
CN   6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-
     [methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Crestor
CN   Rosuvastatin
FS   STEREOSEARCH
MF   C22 H28 F N3 O6 S
CI   COM
SR   CA
LC   STN Files:   BIOSIS, CA, CAPLUS, DRUGNL, DRUGPAT, DRUGUPDATES, SYNTHLINE,
       TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             97 REFERENCES IN FILE CA (1937 TO DATE)
              1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             99 REFERENCES IN FILE CAPLUS (1937 TO DATE)
```